// App-Quantinova.ai

8067 : Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials.

Researchers

Presenter

  • Alexander Edward Dela Cruz Drilon

Principal Investigators

  • Lu Wang

  • Adnan Hasanovic

  • Philippe Joubert

  • Mark G. Kris

  • Gregory J. Riely

  • Marc Ladanyi

  • Naiyer A. Rizvi

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Lenox Hill Hospital, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Dual specificity mitogen-activated protein kinase kinase 1

  • Anaplastic lymphoma Kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Ret Proto-Oncogene

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Cabozantinib

  • Crizotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved